Unique ID issued by UMIN | UMIN000003647 |
---|---|
Receipt number | R000004414 |
Scientific Title | Endoscopic submucosal dissection for early gastric cancer: A prospective study |
Date of disclosure of the study information | 2010/05/21 |
Last modified on | 2015/06/08 16:32:24 |
Endoscopic submucosal dissection for early gastric cancer: A prospective study
Endoscopic submucosal dissection for early gastric cancer: A prospective study
Endoscopic submucosal dissection for early gastric cancer: A prospective study
Endoscopic submucosal dissection for early gastric cancer: A prospective study
Japan |
early gastric cancer
Gastroenterology |
Malignancy
NO
To invastigate the long-term survival, efficacy, and safety of endoscopic submucosal dissection for early gastric cancers ,which was indicated in guidline of Japanese Gastric Cancer Association.
Safety,Efficacy
Exploratory
Pragmatic
Not applicable
5year overall survival rate (OS)
1) OS at UL(-) group
2) OS at UL(+) group
3) Disease free survival rate
4) the rate of avoidance from gastrectomy
5) enbloc resection rate
6) Curative resection rate
7) side effect
8) serious side effect
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Maneuver |
endoscopic submucosal dissection (ESD)
20 | years-old | <= |
Not applicable |
Male and Female
1) a biopsy-proven, differentiated adenocarcinoma, exclude undifferentiated adenocarcinoma.
2)initial and single lesion.
3)tumor depth confined to the mucosa.
4)endoscopically findings
a) UL(-)group, any size
b) UL(+)group, <=30mm
5) possible to enbloc resection
6) less possibility of stricture
7) no findings of any LN swelling, any metastasis on CT(N0,M0).
8) PS is 0 or 1.
9) no synchronus and/or metachronus carcinoma of stomach.
10) no histoly of any cancer.
11)
a) WBC>=3,000/mm3 and <=12,000/mm3
b) Hb>=9.0g/dL
c) Plt>=100,000/mm3
d) AST, ALT<=100 IU/L
e) T-bil <=2.0mg/dL
f) Cr<=2.0mg/dL
12)Voluntary signed and dated written informed consent from all the patients was obtained.
1)continuous medication of anti- coagulate drugs
2)double cancer
3)Pregnant or lactating Women
4)Psychological conditions that may interfere with the patient's compliance and evaluation of the study results
5)Patients with continuous medication of steroid.
6) Patients with active clinically serious infection.
7) Active coronary artery disease less than 3 months prior to study entry
8)Patients with uncontrolled HT.
9)Patients with uncontrolled DM.
10)Patients with respiratory disease with HOT.
1500
1st name | |
Middle name | |
Last name | Kingo Hirasawa |
Yokohama City University Medical Center
Gastroenterological Center
4-57 Urafune-cho, Minami-ku, Yokohama City, 232-0024, Japan
045-261-5656
kingo-h@urahp.yokohama-cu.ac.jp
1st name | |
Middle name | |
Last name | Kingo Hirasawa |
Yokohama City University Medical Center
Gastroenterological Center
4-57 Urafune-cho, Minami-ku, Yokohama City, 232-0024, Japan
045-261-5656
kingo-h@urahp.yokohama-cu.ac.jp
Yokohama City University Medical CenterGastroenterological Center
None
Self funding
NO
横浜市立大学附属市民総合医療センター(神奈川県)
2010 | Year | 05 | Month | 21 | Day |
Unpublished
Completed
2009 | Year | 12 | Month | 01 | Day |
2010 | Year | 05 | Month | 01 | Day |
2015 | Year | 04 | Month | 01 | Day |
2010 | Year | 05 | Month | 21 | Day |
2015 | Year | 06 | Month | 08 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004414